Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Othe... ( LONDON September 16 2011 /- Sil...)

HOME >> MEDICINE >> TECHNOLOGY

Silence Therapeutics Announces Issuance of Japanese Patent for Screening Therapeutics Against Key Pathway Associated with Cancer and Other Diseases

Date:9/16/2011

LONDON, September 16, 2011 /PRNewswire/ --

Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading RNA interference (RNAi) therapeutics company, announces the issuance of patent 4810095 entitled "Use of Protein Kinase N beta" by the Japanese Patent Office. The issued patent covers certain methods for screening a therapeutic agent for the treatment and/or prevention of any disease that involves elevated activity within the PI3-kinase pathway. More specifically, this new intellectual property covers the use of protein kinase N 3 ("PKN3") for screening of therapeutic agents, thus preventing others from using PKN3 for screening purposes. This new patent is broadly directed to various classes of therapeutic agents with the potential to impact the PI3-kinase pathway including short interfering RNA (siRNA) molecules, antibodies and small molecules, among others.

PKN3 is a protein kinase C-related molecule, involved in the PI3-kinase pathway that is believed to play an important role in the growth of cancer cells, as well as metastasis formation. Silence has built a significant research program around PKN3 and the company's lead clinical compound, Atu027, is an RNAi therapeutic that targets PKN3 for the treatment of advanced solid tumors.

"We are excited about consolidating our broad patent portfolio in Japan, especially as it pertains to our high-value PKN3 program," said Dr Klaus Giese, chief scientific officer of Silence Therapeutics. "This patent positions Silence as the exclusive gatekeeper for any project focused on developing therapeutics targeting PKN3, and as interest in this important oncology target continues to grow rapidly, we expect the value of this intellectual property position will also increase significantly."

Silence Therapeutics is proactively building and strengthening its global, diverse and competitive intellectual property portfolio. This provides the Company and po
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/23/2013)... , May 23, 2013 Israel ... Israel 2013 , Israel,s 1 st ... October 14 th -15 th in Tel ... most innovative city in the world by the Wall ... BrainTech Israel 2013 will showcase the latest breakthroughs ...

(Date:5/23/2013)... 2013 Halozyme Therapeutics, Inc. (NASDAQ: ... David A. Ramsay as ... Vice President, Corporate Development at Halozyme. ... his established financial management experience and his recent ... our commercial group for the last four years, ...

(Date:5/23/2013)... May 23, 2013 Omeros Corporation (NASDAQ: ... New Drug Application (IND) to evaluate OMS824 in ... Food and Drug Administration (FDA). OMS824 selectively inhibits ... of the brain linked to a wide range ... and schizophrenia. OMS824 has shown promising results in ...

Breaking Medicine Technology:Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2 Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3 Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2 Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2 Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3 Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4

[0] Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference [0] Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer [0] Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease

... Nov. 14, 2011 Regado Biosciences, Inc., a privately ... with active control agents, announces one poster presentation ... Association (AHA) Scientific Sessions meeting on November 14, ... EST session. All three presentations highlight results from ...

... Corporation ("the Company"), a leading international manufacturer, marketer, and ... today announced its 2011 third quarter financial results. ... For the third quarter of 2011, the ... of 7.8% versus net sales of $223.7 million in ...

Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH Pregis Announces Third Quarter 2011 Financial Results

(Date:5/23/2013)... This news release is available in French . ... Montreal researchers have discovered a novel molecular mechanism that ... other diseases of abnormal growth. In the May 23 ... from the University of Montreal explain how they found ... or prevents cells from dividing. , "Cells normally monitor ...

(Date:5/23/2013)... Six innovative research projects have been awarded grants ... the nation's largest private nonprofit funder of Lyme disease medical ... epidemiology of, and treatment and cure for Lyme and ... support the innovative research being conducted by some of ... the field today,” said Harriet Kotsoris, MD, LRA’s Chief ...

(Date:5/23/2013)... CT (PRWEB) May 23, 2013 Applied ... solutions, announced today that it has added support for ... IDE, the eiConsole for Healthcare. In addition to ... such as LLP, FTP, and Web Services, it now ... The Direct Protocol is a specification of the ...

(Date:5/23/2013)... During pregnancy both the health of ... medical treatments, especially medication. In July 2006, a ... prompted the FDA to warn about a potential link ... as persistent pulmonary hypertension and other malformations (i). ... (SSRI) drugs. SSRI antidepressants are widely prescribed to ...

(Date:5/23/2013)... Each month Dwell magazine is filled ... and electric cars. Nowhere in America are these pages more ... car capital. Thankfully this June, Green Car Journal is bringing ... to Dwell on Design 2013 ( http://www.dwellondesign.com ), ... two days of Dwell on Design, June 21-22, attendees and ...

Breaking Medicine News(10 mins):Health News:Scientists discover how rapamycin slows cell growth 2 Health News:Six Investigators Awarded Lyme Research Alliance Grants 2 Health News:Six Investigators Awarded Lyme Research Alliance Grants 3 Health News:Six Investigators Awarded Lyme Research Alliance Grants 4 Health News:PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release 2 Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 2 Health News:Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects 3 Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 2 Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 3 Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 4 Health News:Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013 5

[0] Scientists discover how rapamycin slows cell growth [0] Six Investigators Awarded Lyme Research Alliance Grants [0] PilotFish Expand’s Healthcare Integration Capabilities with Support for the New Direct Protocol in Its Latest Product Release [0] Personal Injury Law Firm Releases Graphic with the Latest Information on Antidepressants and a Possible Risk of Birth Defects [0] Dwell Media and Green Car Journal Put You in the Driver Seat At Dwell on Design 2013

... ,Time is Brain, SEATTLE, Nov. 14 On ... to activate an advanced telemedicine system,in the emergency rooms ... real-time, 24/7 link between ER physicians and stroke specialists ... Stroke,Program is based. The Swedish TeleStroke Program is ...

... Pa., Nov. 14 Escalon Medical Corp.,(Nasdaq: ESMC ... ended,September 30, 2007. For the first quarter of ... 4% decrease from the $7,168,160, reported in the prior,year ... at the,Company,s Sonomed and Vascular business units, which decreased ...

... Passion for Healthcare, MIAMI, Nov. 14 ... healthcare providers funded by,MTS Health Investors and Oaktree ... E. Burke III to the position of President ... experience to Novis,Pharmaceuticals, with extensive functional expertise in ...

... for November 20, NAPA, Calif., Nov. 14 ... company engaged in the,study of senescense, the science of ... today announced financial results for the,quarter ended September 30, ... $469,000 compared to,$2,027,000 for the same period in the ...

... - Now Families Can Breathe Easier During Cold and ... Nature,s Baby Organics,manufacturers of the finest and purest natural ... Ah-Choo! Chest Rub. Ah-Choo! Chest Rub was,created to bring ... common cold viruses and influenza. "With the unavoidable ...

... NEW YORK, NY November 14, 2007 The ... announced today that they are joining together to create ... of research into drugs and therapies to cure diabetes ... can measure the progress of disease and the effectiveness ...

Cached Medicine News:Health News:Lifesaving TeleStroke Technology Linked to Swedish 2 Health News:Lifesaving TeleStroke Technology Linked to Swedish 3 Health News:Lifesaving TeleStroke Technology Linked to Swedish 4 Health News:Lifesaving TeleStroke Technology Linked to Swedish 5 Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 2 Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 3 Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 4 Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 5 Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 6 Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 7 Health News:Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO 2 Health News:Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO 3 Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 2 Health News:Senetek PLC Reports Third Quarter 2007 Financial Results 3 Health News:JDRF and Lilly partner to fund research to identify beta cell biomarkers 2 Health News:JDRF and Lilly partner to fund research to identify beta cell biomarkers 3

Lifesaving TeleStroke Technology Linked to Swedish Escalon(R) Reports First Quarter Fiscal 2008 Results Novis Pharmaceuticals Announces Hiring of Thomas E. Burke III as President and CEO Senetek PLC Reports Third Quarter 2007 Financial Results Nature's Baby Organics Announces Ah-Choo! Chest Rub JDRF and Lilly partner to fund research to identify beta cell biomarkers

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Zinc Protoporphyrin (ZPP), Whole Blood Industrial ZAP-70 Analysis by Flow Cytometry Yersinia Species Antibody, IgG by Western Blot Yersinia IgA & IgG by Western Blot